TrialPediatric dermatology

Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.

Lawrence F Eichenfield et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.